MedPath

MRI to check Response to chemotherapy in Breast cancer patients

Not Applicable
Conditions
Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Registration Number
CTRI/2021/06/034325
Lead Sponsor
Dr Smiti Sripathi Research Award For Breast Imaging Endowment Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients diagnosed with Early breast cancer being treated with Neoadjuvant chemotherapy. Patients diagnosed with Locally advanced breast cancer, being treated with Neoadjuvant chemotherapy. Baseline and mid-cycle MRI (taken after 3 cycles of chemotherapy) to be taken.

Exclusion Criteria

Patients with metastatic carcinoma of breast.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MRI study (DCE/DWI) of breast, taken Mid-cycle of Neoadjuvant chemotherapy, in Breast cancer patients, effectively helps predict complete pathological response after completion of NAC in Breast cancer patients. <br/ ><br>Timepoint: One and half year
Secondary Outcome Measures
NameTimeMethod
ILTimepoint: -
© Copyright 2025. All Rights Reserved by MedPath